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Abstract
Background: The high rate of cannabis use among patients with first-episode psychosis (FEP), as well as the
associated negative impact on illness course and treatment outcomes, underlines the need for effective
interventions in these populations. However, to date, there have been few clinical treatment trials (of
pharmacological or psychological interventions) that have specifically focused on addressing comorbid cannabis
use among these patients. The aim of this paper is to describe the design of a study protocol for a randomized
controlled trial in which the objective is to assess the efficacy of a specific cognitive behavioral therapy program for
cannabis cessation in patients with FEP compared to standard treatment (psychoeducation).
Methods/design: This is a single-blind randomized study with 1 year of follow-up. Patients are to be randomly
assigned to one of two treatments: (1) specific cognitive behavioral therapy for cannabis cessation composed of
1-hour sessions once a week for 16 weeks, in addition to pharmacological treatment scheduled by the psychiatrist,
or (2) a control group (psychoeducation + pharmacological treatment) following the same format as the
experimental group. Participants in both groups will be evaluated at baseline (pre-treatment), at 16 weeks
(post-treatment), and at 3 and 6 months and 1 year of follow-up. The primary outcome will be that patients in the
experimental group will have greater cannabis cessation than patients in the control group at post-treatment. The
secondary outcome will be that the experimental group will have better clinical and functional outcomes than the
control group.
Discussion: This study provides the description of a clinical trial design based on specific cognitive behavioral
therapy for cannabis cessation in FEP patients, aiming to improve clinical and functional outcome, as well as
tackling the addictive disorder.
Trial registration: NCT02319746 ClinicalTrials.gov Identifier. ClinicalTrials.gov Protocol and Results Registration
System (PRS) Receipt Release Date: 15 December 2014.
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Background
Substance misuse is a common comorbid problem in pa-
tients with first-episode psychosis (FEP), cannabis being
the most commonly abused substance together with al-
cohol in this population [1]. The prevalence of cannabis
use among patients with FEP is notably high, at around
65.7% [2]. This has led to the hypothesis that its use may
have a role in the etiology and evolution of psychosis. It
has been found that cannabis use may act as a risk factor
influencing age of onset of psychosis [3–8]. Further,
young people who abuse cannabis have a higher risk of
developing psychosis than non-abusers, with an earlier
age of onset of psychosis [9]. The risk of developing
psychosis is also related to an early age of onset of use
[3, 9–11], and to the severity of use [3, 9], with a fre-
quency- and dose-dependent response, especially in vul-
nerable individuals [3, 12], increasing the risk in the
general population.
Recently, it has also been suggested that cannabis
abuse in adolescence can cause alterations in the endo-
cannabinoid system (ECS) and that these alterations may
be related to a higher incidence of psychosis and to
some of the symptoms presented. Specifically, some re-
search has shown that frequent use of cannabis can
cause inhibition of the signaling pathways of the main
endocannabinoid, anandamide, in schizophrenia patients
but not in healthy individuals [13]. It has also been re-
ported that FEP patients who are cannabis users have
cognitive deficits associated with structural abnormal-
ities of brain areas with a high level of expression of can-
nabinoid receptor type 1 (CB1) [14, 15]. Further, it has
been shown that the intake of exogenous cannabinoids
could alter synaptic plasticity mediated by the ECS, pos-
sibly affecting brain maturation during adolescence, and
in turn, neurodevelopmental processes [16].
The ECS is an endogenous homeostatic system with mul-
tiple physiological functions and is activated in response to
various different stimuli and under different neuropatho-
logical conditions. It is composed of a series of lipid media-
tors, known as endocannabinoids, anandamide and
2-arachidonoylglycerol being the most studied; their
two classical receptors coupled to G protein, CB1 and
cannabinoid receptor type 2 (CB2); and enzymes
responsible for its synthesis, N-acyl-phosphatidyletha-
nolamine-selective phospholipase C (NAPE-PLC) and
diacylglycerol lipase (DAG-L), and degradation, fatty
acid amide hydrolase (FAAH) and monoacylglycerol
lipase (MAG-L).
Some studies have linked the ECS with psychotic ill-
ness, especially focusing on CB1 and CB2. In particular,
lower expression of CB1 has been observed in several
brain regions of individuals with schizophrenia [17] and
it has also been shown that CB2 loss of function (due to
polymorphisms such as Q63R) is associated with an
increased susceptibility to schizophrenia [18]. Remission
of symptoms in schizophrenia has also been associated
with significant changes in messenger ribonucleic acid
(mRNA) levels of CB2 in peripheral blood mononuclear
cells [19]. With respect to other components of the ECS,
there is much less information, but alterations in the
levels of anandamide have been found in the cerebro-
spinal fluid of patients with schizophrenia [20].
There is empirical evidence for an influence of canna-
bis on the course and outcome of psychosis [21, 22].
Cannabis use in early psychosis is correlated with poor
adherence to pharmacological treatment [2, 23, 24], the
severity of psychotic symptoms [22] and the risk of re-
lapse [2, 21, 23, 24]. Moreover, patients with FEP who
use cannabis have a poorer functional outcome at
follow-up [22, 25–27]. On the other hand, patients with
FEP who stop using cannabis experience a slow but
steady improvement over time in clinical and functional
outcome [21].
Cannabis use, due to its influence on the development
and prognosis of the disease, has become a target for the
prevention and treatment of patients with FEP. Such pa-
tients, unlike chronic psychotic patients, show a greater
variation in the frequency and intensity of cannabis use
and greater motivation for change at baseline [28].
Therefore, it is essential to intervene in the early stages
of the disease, before cannabis use becomes established.
What is more, early intervention may be able not only
to reduce but also to detect this type of substance abuse
in patients with FEP.
In a systematic review, Ruiz de Azúa García et al. [29]
concluded that several studies have shown that psychoe-
ducation as an adjuvant to pharmacological treatment is
effective in improving negative symptoms and function-
ality (Lambeth Early Onset Team Study, UK; Personal
Assessment and Crisis Evaluation, Australia; OPUS
Scandinavia, Denmark; Early Psychosis Prevention and
Intervention Centre, Australia). Evidence suggests that
cognitive behavioral therapy may also be effective in FEP
[30]. However, despite the recognized clinical conse-
quences of cannabis use in early psychosis [3–6], only a
few trials have evaluated clinical treatments as a specific
intervention to reduce cannabis use in this population.
These studies have investigated interventions based on
motivational interviewing [31] or combined interven-
tions based on motivational interviewing and cognitive
behavioral therapy [32–35]. Generally, the results ob-
tained failed to clearly indicate whether the interventions
were effective in terms of reducing cannabis use and/or
improving clinical outcomes at follow-up. The exception
was the study conducted by Madigan et al. [34], in which
patient quality of life improved at post-treatment. Fur-
ther, the small sample sizes and the absence of an appro-
priate treatment-as-usual control condition in these
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studies indicate that it is not possible to draw definite
conclusions.
From reviewing the literature, we conclude that there
is an urgent need to develop effective specific interven-
tions to reduce cannabis use as part of comprehensive
treatment programs for patients with psychosis. Overall,
the effectiveness of interventions and the type of ap-
proach used are unclear [31–35]. There is also a need
for interventions based on more precise knowledge of
individual differences in patterns of use as well as of fac-
tors that maintain or inhibit substance abuse in young
people with FEP.
The main aim of this article is to describe the design of
a randomized controlled trial focused on comparing the
efficacy of a specific cognitive behavioral therapy program
for cannabis cessation with standard treatment in patients
with FEP who are cannabis users. The study design, as-
sessment and intervention program are described.
The specific objectives of the study are:
1. To assess whether a specific cognitive behavioral
therapy program for cannabis cessation is associated
with a greater reduction in use of cannabis than
standard treatment
2. To assess whether this type of program for cannabis
cessation is associated with better outcomes of the
psychotic disorder (i.e., reduction in symptoms and
improvement in psychosocial functioning) in the
follow-up than standard treatment
3. To analyze the relation between cannabis abstinence
and clinical and functional outcomes of patients
4. To determine whether there are systemic alterations
in the components of the ECS and, if so, whether a
specific cognitive behavioral therapy program for
cannabis cessation is able to normalize such
alterations
5. To assess whether normalization of elements of the
ECS is directly related to reductions in symptoms
and improvements in psychosocial functioning
attributable to the proposed specific treatment
Methods
Design
This is a randomized study with 1 year of follow-up. The
intervention programs will be offered at Araba University
Hospital and biological samples will be analyzed at
Complutense University of Madrid.
The randomized clinical trial was registered in 2014
(ClinicalTrials.gov Identifier NCT02319746). This clin-
ical trial fulfills the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) Checklist
(Additional file 1). The efficacy of a specific treatment
program for cannabis abuse (cognitive behavioral
treatment + pharmacological treatment) will be compared
to that of standard treatment (psychoeducation +
pharmacological treatment) in patients with FEP who
are cannabis users.
Participants
FEP patients who are cannabis users and meet the inclu-
sion criteria (listed below) are to be included and ran-
domly assigned to one of the two treatment groups. The
sample size calculation was performed using data pub-
lished in the literature related to the main theme of the
study (Bonsack et al., 2011 [31]; Edwards et al., 2006
[32]; Hjorthøj et al., 2012; Madigan et al., 2013 [34]) and
using Ene 2.0 software. To achieve a power of 80% to
detect differences from the null hypothesis, H0: μ1 = μ2,
using a bilateral Student’s t test for two independent
samples, with a significance level of 5%, we need to in-
clude 30 patients in the experimental group and 30 pa-
tients in the control group, meaning a total of 60
patients for the study.
Inclusion criteria
The study inclusion criteria for both groups are:
1. Being diagnosed as having had a first psychotic
episode: (i.e., schizophrenia, schizophreniform
disorder, schizoaffective disorder, delusional disorder,
bipolar disorder, atypical psychosis, brief psychotic
disorder, or major depressive disorder with psychotic
symptoms) according to the revised fourth edition of
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) [36]
2. Being a regular cannabis user (Table 1):
Dependence or abuse of cannabis according to
Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-
TR) criteria [36].
Dependence or abuse of cannabis according to the
scores of the European Addiction Severity Index
(EUROP-ASI) [37, 38] (scores of 4 to 7: abuse;
scores of 8 to 9: dependence)
3. Aged between 15 and 40 years. In the case of minors
(under 18 years of age), written informed consent
will be requested from their parents or guardians
4. Being in remission from a first psychotic episode
(the patients being required to be in remission,
without any relapses in a period no more than 5
years from the first psychotic episode)
Exclusion criteria
The study exclusion criteria for both groups are:
1. Presenting organic brain pathology
2. Presenting mental retardation according to DSM-IV-
TR criteria
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Randomization
Patients are to be randomly assigned to one of the two
treatment groups by permuted block randomization with
a block size of 4 and a 1:1 allocation using a computer-
generated random sequence. The allocation sequence
will be prepared by an independent person not otherwise
involved in the trial.
Assessment
Data collection is to be based on an assessment protocol
for gathering data on sociodemographic, clinical and can-
nabis/other substance use-related variables. All patients
are to be assessed at baseline, post-treatment and in the
follow-up period (at 3 and 6 months and 1 year of follow-
up from the end of the treatment program) (Table 2).
Sociodemographic variables
Data on sociodemographic variables (age, gender, educa-
tional level, socioeconomic level, employment status,
family history of psychiatric disorders) are to be col-
lected at baseline.
Cannabis/other substance use-related variables
1. Variables related to cannabis/other substance use
include frequency of use, dose, age of onset of use
and history of use (years)
2. Severity of cannabis/other substance use is assessed
with the EUROP-ASI [37, 38] and the Cannabis Use
Problems Identification Test (CUPIT) [39]
The EUROP-ASI, an adaptation of the Addiction
Severity Index (fifth version), is a structured interview
for clinical practice and research. It is designed to assess
severity of the substance use problem and makes it pos-
sible to monitor and quantify changes in problems com-
monly associated with substance abuse. Translated into
practically all European languages, the reliability and
validity of EUROP-ASI are well established [40–44] and
it has been shown to have high internal consistency
(Cronbach’s alpha coefficient >0.70) [41, 42, 44, 45] and
moderate-excellent interrater reliability (interclass cor-
relation coefficient 0.62–0.99) [43, 44].
Table 1 Classification of cannabis use for selection of participants
Severity of
consumption
DSM-IV-TRa criteria for abuse or dependence Europ-ASIb scores
Dependence Meet at least minimal DSM-IV-TR criteria for cannabis dependence 8–9
Abuse Meet ≥1 DSM-IV-TR criteria for cannabis abuse 4–7
Use Meet DSM-IV-TR criteria for cannabis abuse but not the duration criterion (≥12 months)
or ≥12 months of use but do not meet any DSM-IV-TR criteria for cannabis abuse
2–3
No use No significant symptoms 0–1
aRevised Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [37]
bEuropean Addiction Severity Index (Europ-ASI) [37,38]
Table 2 Assessment protocol
Assessments Pre-treatment Post-treatment Follow-upa
Sociodemographic variables X
Cannabis/other substance use-related variables
Use X X X X X
Severity X X X X X
Clinical variables
Diagnosis X X X X X
Clinical severity X X X X X
Illness awareness X X X X X
Medication adherence X X X X X
Clinical symptomatology X X X X X
Psychosocial functioning X X X X X
Biological variables
Peripheral blood mononuclear cells X X X X X
Toxins in urine X X X X X
aFollow-up: 3 and 6 months and 1 year of follow-up from the end of the intervention program
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CUPIT is a brief self-report screening instrument for
the detection of currently and potentially problematic
cannabis use. It is composed of 16 items and has dem-
onstrated good test-retest (0.88 to 0.99) and internal
consistency reliabilities for the two derived subscales,
“dependence” (0.92, whole sample) and “problems” (0.90
adults, 0.79 adolescents), and it has reliably discrimi-
nated diagnostic subgroups (no diagnosis, abuse/harmful
use, dependence) across the problem severity continuum
(diagnostic utility) [39].
Clinical variables
1. Diagnosis
Patients are diagnosed according to the DSM-IV-TR
criteria using the Structured Clinical Interview for the
Diagnostic and Statistical Manual of Mental Disorders,
Axis I Disorders (SCID-I) [45]. This interview is to be
carried out independently but at the same time by two
experienced clinicians, to confirm inter-rater reliability
in the diagnosis of patients
2. Clinical severity
The Clinical Global Impression Scale (CGI) [46] is
used to assess symptom severity, global
improvement and therapeutic response. It is a
3-item observer-rated scale. Items 1 and 2 are
rated on a seven-point scale; and item 3 is rated
on a five-point scale, from 0 to 4 (taking into
account therapeutic efficacy and treatment-
related adverse events)
3. Illness awareness
The illness awareness of patients is measured using
the Scale to assess Unawareness in Mental
Disorders (SUMD) [47, 48]. This scale explores the
thoughts and beliefs of patients regarding their
illness and its pharmacological treatment
4. Medication adherence
The type of pharmacological treatment is recorded
and medication adherence is estimated with the 4-
item Morisky Medication Adherence Scale [49, 50].
It assesses attitudes of patients towards their
treatment. Patients with a score of 4 were
considered to have good adherence, while those
with a score between 0 and 3 were classified as
having poor adherence
5. Clinical symptomatology
Psychotic symptoms are measured using Positive
and Negative Syndrome Scale (PANSS) [51, 52].
The PANSS is a relatively brief interview used for
measuring positive, negative and general symptoms
of patients with schizophrenia. The ratings provide
summary scores on a 7-item positive scale, a 7-item
negative scale and a 16-item general psychopathology
scale.
Depressive symptoms are measured with the
Hamilton Depression Rating Scale (HDRS-21)
[53, 54]. This is a 21-item scale that assesses the
severity of depressive symptoms (range: 0–52)
Manic symptoms are measured using the Young
Mania Rating Scale (YMRS) [55, 56]. This is an
11-item scale used to assess the severity of manic
symptoms (range: 0–60).
Anxiety symptoms are measured using the
Hamilton Anxiety Scale (HAM-A) [57, 58]. This
has been developed to measure the severity of
anxiety symptoms, both psychic anxiety (mental
agitation and psychological distress) and
somatic anxiety (physical complaints related to
anxiety)
6. Psychosocial functioning
The functioning of patients is measured using the
Functioning Assessment Short Test (FAST) [59].
The FAST is a brief instrument designed to assess
functional impairment in severe mental disorders.
The 24 items of the scale cover six specific areas of
functioning: autonomy, occupational functioning,
cognitive functioning, financial issues, interpersonal
relationships and leisure time
Biological variables
To assess whether the treatment program is able to
normalize any changes in the components of the
ECS, peripheral blood mononuclear cells (10 ml of
venous blood anticoagulated with ethylenediamine-
tetraacetic acid (EDTA)) are to be collected at base-
line, at post-treatment and at 3 and 6 months and 1
year of follow-up. In peripheral blood mononuclear
cells, the following elements of the endogenous can-
nabinoid system are to be measured: synthesis en-
zymes (NAPE-PLD, DAG-L), degrading enzymes
(FAAH, MAG-L), and receptors (CB1 and CB2) by
Western blot (protein) and reverse transcription-
polymerase chain reaction (mRNA).
Toxins in urine are assessed with an immunochromato-
graphic test to detect drug metabolites at baseline, at ses-
sions 4 and 8 of the psychological treatment, post-
treatment, and at 3 and 6 months and 1 year of follow-up.
Procedure
Patients will be assessed after being informed of the objec-
tives of the study and giving their informed consent to
participate. All participants will be evaluated individually
and will be randomly assigned to one of two treatment
groups. Data will be collected following an assessment
protocol (see “Assessment” section) that will be imple-
mented at baseline, post-treatment and in the follow-up
period (at 3 and 6 months and 1 year of follow-up from
the end of the intervention program) (Fig. 1).
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Statistical analysis
IBM SPSS version 23 will be used for the statistical ana-
lysis. The sociodemographic characteristics of the pa-
tients will be analyzed using descriptive statistics.
Differences between the two intervention groups (cogni-
tive behavioral therapy versus psychoeducation) will be
analyzed using the χ2 test (or Fisher’s test where n ≤5)
for categorical variables and the Student’s t test or
Mann-Whitney U test (depending on the distribution of
the data) for continuous variables.
The differences in cannabis use reduction between
two intervention groups will be analyzed using
Student’s t test and/or the Mann-Whitney U test and
mixed models. Effect sizes will be calculated for dif-
ferences in cannabis abstinence based on Cohen’s d
or r [60] for Student’s t test and the Mann-Whitney
U test, respectively. The results will be interpreted as
small if d values are between .2 and .49, medium if d
values are between .5 and .79, and large if d values
are higher than .8.
Differences in efficacy between the interventions in
terms of clinical and functional outcomes of patients will
be analyzed with repeated measures models (baseline,
post-treatment, 3 and 6 months and 1 year of follow-up)
and logistic regressions.
Furthermore, whether cannabis abstinence is asso-
ciated with better clinical and functional outcomes
will be analyzed using linear regression models for
continuous dependent variables, and Poisson regres-
sion models for categorical dependent variables.
Finally, the biological data of patients will be studied in
conjunction with clinical data using multivariate analyses.
Specifically, the possible alterations in the components of
the ECS and the influence of the specific cognitive behav-
ioral therapy program for cannabis cessation on the
normalization of ECS will be analyzed using repeated
measures models, mixed models or analysis of covariance.
Further, the relation between normalization of elements of
the ECS and improvement in symptoms and psychosocial
functioning, attributable to the specific treatment, will be
assessed by regression models.
Intervention programs
Patients are to be randomized into two treatment
groups:
1. The experimental group will receive specific
cognitive behavioral therapy for cannabis cessation
composed of 1-hour sessions once a week for 16
weeks, in addition to pharmacological treatment
prescribed by the psychiatrist
2. The control group will receive the standard treatment
(psychoeducation + pharmacological treatment)
following the same format as the experimental group,
that is, 1-hour sessions of psychoeducation once a
week for 16 weeks, in addition to pharmacological
treatment prescribed by the psychiatrist
1. Experimental group (specific cognitive behavioral
therapy for cannabis cessation + pharmacological
treatment)
The intervention program is focused on cannabis
cessation, identification of prodromes, improving
illness awareness, adherence to treatment,
psychosocial functioning and relapse prevention.
The content of the sessions is as follows:
 Sessions 1–3: the first three sessions involve
motivational interviewing [61], followed by brief
psychoeducation focused on general information
about cannabis and psychosis: (a) psychosis and
substance use, (b) medication and treatment
adherence, (c) awareness of the vulnerability, (d)
recognition of symptoms, (e) healthy lifestyle,
and (f ) risk and protective factors.
Do FEP patients meet 
inclusion criteria?
Obtain informed 
consent
Patients excluded
RANDOMIZATION
Experimental group Control group
BASELINE ASSESSMENT
INTERVENTION 
PROGRAM
FOLLOW-UP 
ASSESSMENTS 
3 months of follow-
up from the end of 
the intervention 
program
6 months of follow-
up from the end of 
the intervention 
program
1 year of follow-up
from the end of the 
intervention 
program
Cognitive behavioral 
therapy for cannabis 
cessation
Psychoeducation 
Yes No
Fig. 1 Study procedure
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 Sessions 4–8: the second part of the program is
focused on commitment to change [62] and
includes the following aspects:
Behavioral therapy:
o Anxiety management techniques
o Stimulus control
o In-vivo exposure therapy with response
prevention, identifying triggers and beliefs that
could lead to substance use and exacerbation of
psychotic symptoms and exposure to such triggers
Cognitive therapy:
o Specific techniques for managing thoughts
about the consumption and use of cannabis
and other substances (craving/abstinence) and
symptom management
o Cognitive restructuring; identifying and
refuting cognitive distortions
o Training in problem solving
o Training in social skills; assertiveness; skills
to refuse drugs and changes in lifestyle.
 Sessions 10–12: the third part of the program
includes a specific intervention for relapse
prevention, focused on the identification of high-
risk situations that could lead to maintenance of
substance use and increased severity and
chronicity of psychotic symptoms, as well as the
teaching of coping skills for such situations
2. Control group (standard treatment: psychoeducation +
pharmacological treatment)
The aim of the psychoeducation is to enable patients to
understand and be able to manage their disease, providing
them with tools and skills for symptom management, to
avoid relapse and contribute to their well-being. Psychoe-
ducation sessions include the following modules:
Session 1: What is a first psychotic episode?
Session 2: Awareness of vulnerability
Session 3: Recognition of symptoms
Sessions 4–5: Prevention of relapses: risk and protective
factors
Session 6: Adherence to treatment
Session 7: Healthy lifestyle: sleep and sexuality
Session 8: Healthy lifestyle: misuse of drugs
Session 9: Anxiety management techniques I
Session 10: Anxiety management techniques II
Session 11: Social skills: assertive communication techniques
Session 12: Problem-solving techniques
Discussion
The randomized clinical trial described in this paper
represents an innovation related to the development of
therapeutic procedures based on evidence. All patients di-
agnosed with severe mental illness should be included
early in a program of effective treatment. Specifically, the
effective treatment of psychotic disorders in patients with
comorbid substance abuse is an important goal in clinical
practice. Mental health drug addiction services are often
run in parallel to other health care services with different,
sometimes conflicting, approaches and this further hin-
ders the treatment of these patients, who may have diffi-
culty integrating into standard treatments and require
specific programs. Ideally, interventions for these patients
should be tailored to their specific needs. However, this is
often not possible given the dichotomy between mental
health and substance abuse treatment providers. On the
other hand, no clinical treatment trials conducted to date
have shown any specific interventions to have effective re-
sults in terms of reducing cannabis use and/or improving
clinical outcomes in the follow-up of this population.
The results of our study may have a significant impact
on both prognosis and treatment, and may be useful for
identifying patients who need early and continuous
therapeutic interventions from the onset of their illness,
in addition to specific interventions to tackle the impact
of drug use. The results of this study should also help us
to meet the social and health needs of this population,
guiding the use of therapeutic resources that may be re-
quired early in treatment to decrease the severity of the
psychopathology and improve the prognosis of patients.
This kind of intervention is a promising therapeutic ap-
proach not only to treat psychosis, but also to discover
and reduce substance abuse in individuals experiencing
a first psychotic episode.
Finally, the design of early intervention strategies and
the development of a clinical guideline setting out a spe-
cific treatment program for patients with FEP who are
cannabis users would enable more efficient management
of health resources. That is, besides enriching treatment
programs currently available, this study will help to
standardize this new treatment, thereby serving the pro-
fessional community, and in turn, patients will benefit
from the results of this research.
The limitations of this study are mostly related to typ-
ical limitations of this type of clinical trial with a longitu-
dinal design, in particular, the sample size. Another
limitation is that this type of patient with a dual diagno-
sis often has a lack of illness awareness, and poor insight
and treatment adherence, and hence there may be diffi-
culties in completion of the program and attendance to
follow-up visits by participants. These factors should be
taken into consideration in interpreting the efficacy of
the therapy and the impact of intervention on the clin-
ical and functional outcomes of patients.
Trial status
Patient recruitment has not been completed at the time
of submission.
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